- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00630305
Endothelial Bleb Response With Toric Lenses
January 11, 2017 updated by: Johnson & Johnson Vision Care, Inc.
Evaluation of the Short-Term Corneal Endothelial Response to Wear of Toric Soft Contact Lenses in Asian Eyes
Evaluate the short-term corneal response of oxygen deprivation when using toric contact lenses.
The response will be noted by endothelial bleb formation in both open eye and closed eye state.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Interested subjects who meet the entry criteria for the study will be scheduled for four sessions of approximately 30 minutes duration each.
Informed consent obtained.
Baseline measurements of visual acuity and corneal and conjunctival physiology will be recorded.
An examination of the endothelium of the corneas will be conducted using the specular microscope, readings obtained at 5 locations on each cornea: one in the centre and one in each of the superior, inferior, nasal and temporal peripheral regions, approximately 2mm from the limbal margin.
The assigned lenses will be inserted according to a fixed-allocation randomization schedule, where each session follows an optimized 2- period simultaneous crossover design, which specifies lenses to be used in each of the four sessions.
Lenses will be worn for 20 minutes and then removed.
Endothelial specular microscopy will be conducted at 20 minutes with the lenses on.
A final evaluation of corneal and conjunctival physiology will be performed prior to subject clearance from the study.
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Auburn Village, Victoria, Australia, 3122
- Brennan Consultants 110 Auburn Rd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Successful soft contact lens wear in daily mode for a minimum of 1 month prior to start of the study without experiencing difficulties or contact lens related complications.
- At least 18 years of age and mentally competent to sign an informed consent form.
- Healthy eyes and no use of ocular medication.
- Similarity of optical parameters between eyes.
- Physical appearance typical of Asian eyes
Exclusion Criteria:
- A medical or ocular condition that may influence the outcome of this trial.
- Current use of ocular/systemic medication that may influence the outcome of this trial.
- Failure to wear soft lenses for 2 weeks prior to the start of the study.
- Current enrolment or participation in another clinical study.
- Current state of pregnancy or breastfeeding
- Anisometropia greater than 1.00D (equivalent sphere).
- Unequal acuities between eyes (greater than 1 line)
- Unequal corneal curvatures (>1.00D)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Session A
Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session.
Each subject participated in all four sessions.
Session A only contains senofilcon A toric and alphafilcon A toric lenses.
|
Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
|
|
Other: Session B
Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session.
Each subject participated in all four sessions.
Session B only contains senofilcon A toric and alphafilcon A toric lenses.
|
Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
|
|
Other: Session C
Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session.
Each subject participated in all four sessions.
Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
|
Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
|
|
Other: Session D
Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session.
Each subject participated in all four sessions.
Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
|
Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial Bleb Areas on Cornea: Session A- Open Eye
Time Frame: 20 minutes post-lens insertion
|
Mean area of endothelial blebs in the following corneal locations: Central, Nasal, Temporal, Inferior, Superior.
A masked observer performed the analysis by subjectively selecting a region in a given image that provided an optimal balance of maximum area and clarity of cell outlines.
Blebs were then outlined manually and the software calculated the area of blebs.
The different sessions are reported showing results for each lens according to the lens worn in the contralateral (contra) eye.Open eye sessions simulated the subjects normal ocular behavior during waking hours; closed eye sessions simulated ocular activity during duration of closed eye activity, such as sleeping.
Results are reported as the mean percent difference between the stated test (senofilcon A) and the control lens (alphafilcon A, lotrafilcon B), after 20 minutes of wear, for each testing scenario.
|
20 minutes post-lens insertion
|
|
Endothelial Bleb Areas on Cornea: Session B- Closed Eye
Time Frame: 20 minutes post-lens insertion
|
Mean area of endothelial blebs in the following corneal locations: Central, Nasal, Temporal, Inferior, Superior.
A masked observer performed the analysis by subjectively selecting a region in a given image that provided an optimal balance of maximum area and clarity of cell outlines.
Blebs were then outlined manually and the software calculated the area of blebs.
The different sessions are reported showing results for each lens according to the lens worn in the contralateral (contra) eye.Open eye sessions simulated the subjects normal ocular behavior during waking hours; closed eye sessions simulated ocular activity during duration of closed eye activity, such as sleeping.
Results are reported as the mean percent difference between the stated test (senofilcon A) and the control lens (alphafilcon A, lotrafilcon B), after 20 minutes of wear, for each testing scenario.
|
20 minutes post-lens insertion
|
|
Endothelial Bleb Areas on Cornea: Session C- Open Eye
Time Frame: 20 minutes post-lens insertion
|
Mean area of endothelial blebs in the following corneal locations: Central, Nasal, Temporal, Inferior, Superior.
A masked observer performed the analysis by subjectively selecting a region in a given image that provided an optimal balance of maximum area and clarity of cell outlines.
Blebs were then outlined manually and the software calculated the area of blebs.
The different sessions are reported showing results for each lens according to the lens worn in the contralateral (contra) eye.Open eye sessions simulated the subjects normal ocular behavior during waking hours; closed eye sessions simulated ocular activity during duration of closed eye activity, such as sleeping.
Results are reported as the mean percent difference between the stated test (senofilcon A) and the control lens (alphafilcon A, lotrafilcon B), after 20 minutes of wear, for each testing scenario.
|
20 minutes post-lens insertion
|
|
Endothelial Bleb Areas on Cornea: Session D- Closed Eye
Time Frame: 20 minutes post-lens insertion
|
Mean area of endothelial blebs in the following corneal locations: Central, Nasal, Temporal, Inferior, Superior.
A masked observer performed the analysis by subjectively selecting a region in a given image that provided an optimal balance of maximum area and clarity of cell outlines.
Blebs were then outlined manually and the software calculated the area of blebs.
The different sessions are reported showing results for each lens according to the lens worn in the contralateral (contra) eye.Open eye sessions simulated the subjects normal ocular behavior during waking hours; closed eye sessions simulated ocular activity during duration of closed eye activity, such as sleeping.
Results are reported as the mean percent difference between the stated test (senofilcon A) and the control lens (alphafilcon A, lotrafilcon B), after 20 minutes of wear, for each testing scenario.
|
20 minutes post-lens insertion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Noel A Brennan, McOptom PhD, Brennan Consultants
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
February 28, 2008
First Submitted That Met QC Criteria
February 28, 2008
First Posted (Estimate)
March 7, 2008
Study Record Updates
Last Update Posted (Actual)
March 3, 2017
Last Update Submitted That Met QC Criteria
January 11, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-0726
- JJO0717
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ametropia
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
European Vision Institute Clinical Research NetworkCompletedNormal Subjects, AmetropiaSpain
-
Alcon ResearchCompletedMyopia | Hyperopia | Refractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
Unicon Optical Co. Ltd.Recruiting
Clinical Trials on alphafilcon A toric
-
Johnson & Johnson Vision Care, Inc.Foresight Regulatory Strategies, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Foresight Regulatory Strategies, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Alcon ResearchCompletedRefractive Error | Astigmatism | Myopia
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.CompletedAstigmatismUnited Kingdom
-
CooperVision, Inc.CompletedAstigmatismCanada, United States
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
CooperVision, Inc.CompletedPresbyopia | AstigmatismUnited Kingdom
-
CooperVision, Inc.Completed